uniQure Appoints Matthew Kapusta as Chief Financial Officer

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
uniQure Appoints Matthew Kapusta as Chief Financial Officer

AMSTERDAM, the Netherlands, Jan. 9, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that Matthew Kapusta has joined uniQure's management team as Chief Financial Officer effective January 1, 2015. Mr. Kapusta brings to the Company nearly 20 years of life science industry experience from investment banking and finance, as well as corporate development positions. In addition, uniQure announced the following changes to its Supervisory Board: François Meyer, a member of the Supervisory Boards of uniQure and its predecessor company AMT since 2010, and Sander Slootweg, Managing Partner of Forbion Capital Partners and Supervisory Board Member from 2006 to 2008 and again starting in 2012, will step down from the Supervisory Board. Philip Astley-Sparke, who has overseen uniQure's U.S. operations over the past two years, will be nominated for appointment to the Supervisory Board and will pass his operational responsibilities to Mr. Kapusta, who will be based in uniQure's Massachusetts manufacturing facility. Additionally, Prof. Hugo Katus, who is recognized as one of the leading heart surgeons and clinicians worldwide, has agreed to be nominated for appointment to the Supervisory Board. These changes are intended to add relevant breadth of experience and independence to the uniQure Supervisory Board.

"As a former life sciences investment banker, Matthew has led many financial transactions and he has acquired a tremendous amount of experience as an executive in life science companies," said Jörn Aldag, CEO of uniQure. "We are extremely grateful to François and Sander for their valued contributions to transitioning uniQure into a publicly listed company. Likewise, we thank Philip, who joined uniQure's leadership team in 2013 to establish our US presence, including the completion of our advanced gene therapy manufacturing facility, for his immense commitment and dedication. We are delighted to have his input as a Supervisory Board member in the future. Prof. Hugo Katus will add vast experience as a cardiovascular expert and clinician."

Mr. Kapusta joins uniQure from AngioDynamics (Nasdaq: ANGO), where he was Senior Vice President responsible for corporate development, strategic planning and national accounts. Prior to this, he served as Vice President, Finance, for Smith & Nephew Orthopaedics (FRA: NPW1). He has held several positions in the investment banking and equity space, including his role as Managing Director, Healthcare Investment Banking at Collins Stewart, and leadership positions at Wells Fargo Securities and Robertson Stephens. Mr. Kapusta holds a Master of Business Administration from New York University and an undergraduate degree in business from University of Michigan and earned his Certified Public Accountant license in 1996.

About uniQure
uniQure is delivering on the promise of gene therapy through single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders. We are engaged in multiple partnerships and have obtained regulatory approval of our lead product, Glybera, in the European Union for a subset of patients with LPLD. www.uniQure.com

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the risk of cessation or delay of any of the ongoing or planned clinical studies and/or development of our product candidates, the risk of delay or failure to successfully commercialize or obtain further regulatory approval of Glybera, and the risk that our collaborations with Chiesi or our other collaboration partners will not continue or will not be successful. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's Form 20-F filed with the Securities and Exchange Commission dated April 25, 2014. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure:
Aicha Diba
Investor Relations
Direct : +31 20 240 6100
Main: +31 20 240 6000
a.diba@uniQure.com

Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494 or +1 781 235 3060
gschweitzer@macbiocom.com

HUG#1885613

Scroll down for more posts ▼

Top 10 Most Recent News Articles

191 Schools Honored for Academic Growth Success

Updated Category News Views 44

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 34

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 176

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 59

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Monotype Unveils Font Tool for Adobe: A Game-Changer?

Updated Category News Views 12

Monotype Connect: Fonts Meet Convenience Imagine fighting through a blizzard with a flashlight. That's how designers juggle fonts without a central tool. Well, Monotype's got them covered with the new Connect panel for Adobe apps—a beacon of efficiency spotted at Adobe MAX 2026 in Miami Beach. Efficiency and Brand Unity: Partners in Design Now, here’s why this isn’t...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 41

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 259

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 120

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 103

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Boot Barn Holdings Inc's Updated Short Interest Trends

Updated Category News Views 216

Boot Barn Holdings Inc Short Interest Overview Boot Barn Holdings Inc (NYSE: BOOT) recently reported a decrease in its short interest as a percentage of the float, showing a 3.28% drop since the last report. Currently, there are approximately 3.45 million shares sold short, representing 15.33% of all the regular shares available for trading. Based on recent trading...

Continue Reading
Kura Oncology's Inducement Grants: Enhancing Employment Opportunities

Updated Category News Views 138

Kura Oncology's New Inducement Grants for Employees Kura Oncology, Inc., a prominent clinical-stage biopharmaceutical company, has recently made headlines with its innovative approach to employee engagements. This dynamic company is dedicated to the advancement of precision medicines that promise better treatments for cancer patients. To strengthen its workforce, Kura...

Continue Reading
Star Power and Dark History Fuel 'Hell's Half-Acre'

Updated Category News Views 70

A Gripping True Crime Tale Hits the Screen Does the open prairie of the 1870s Kansas and a family of killers strike a chill down your spine? If not, just wait until you get an eyeful of 'Hell's Half-Acre,' a film delving into America's first serial killing 'family.' Nicholas Nicastro, not one to shun bold storytelling, is the power wheel behind this upcoming...

Continue Reading
The Block Unveils Campus: A New Era in Crypto Education

Updated Category News Views 371

The Block Unveils Campus: A Revolutionary Education Platform The Block has unveiled its latest initiative, Campus by The Block, a comprehensive education and certification platform tailored specifically for the crypto industry. This innovative platform was introduced during The Block's inaugural global conference, highlighting its commitment to overcoming the challenges...

Continue Reading
Makino Milling Seeks Modifications to Nidec's Takeover Proposal

Updated Category News Views 825

Makino Milling Requests Changes to Nidec's Bid In a recent statement, Japanese machine tool manufacturer Makino Milling Machine has actively engaged with Nidec regarding an unsolicited takeover bid. This interaction highlights the ongoing dynamics within the industrial machinery sector and reflects the strategic decisions being made by companies in Japan. Details of the...

Continue Reading